TYVASO DPI Drug Patent Profile

When do Tyvaso Dpi patents expire, and what generic alternatives are available?

Tyvaso Dpi is a drug marketed by United Therap and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and nine patent family members in seventeen countries.

The generic ingredient in TYVASO DPI is treprostinil. There are nineteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the treprostinil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tyvaso Dpi

A generic version of TYVASO DPI was approved as treprostinil by SANDOZ on November 30^th, 2017.

Summary for TYVASO DPI

International Patents:	109
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	26
Patent Applications:	1,687
Drug Prices:	Drug price information for TYVASO DPI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYVASO DPI
What excipients (inactive ingredients) are in TYVASO DPI?	TYVASO DPI excipients list
DailyMed Link:	TYVASO DPI at DailyMed

See drug prices for TYVASO DPI

Recent Clinical Trials for TYVASO DPI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Diego	EARLY_PHASE1
United Therapeutics	EARLY_PHASE1
Yuh Chin T Huang, MD, MHS	PHASE1

See all TYVASO DPI clinical trials

Pharmacology for TYVASO DPI

Drug Class	Prostacycline Vasodilator
Physiological Effect	Vasodilation

US Patents and Regulatory Information for TYVASO DPI

TYVASO DPI is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-005	Oct 24, 2024		RX	Yes	Yes	11,723,887			Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-005	Oct 24, 2024		RX	Yes	Yes	10,772,883		Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-001	May 23, 2022		RX	Yes	Yes	11,357,782
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-003	May 23, 2022		RX	Yes	Yes	11,723,887			Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-004	May 23, 2022		RX	Yes	Yes	10,421,729		Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-002	May 23, 2022		RX	Yes	Yes	11,357,782
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-001	May 23, 2022		RX	Yes	Yes	9,593,066			Y

Expired US Patents for TYVASO DPI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-003	May 23, 2022	10,130,685
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-005	Oct 24, 2024	10,130,685
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-001	May 23, 2022	10,130,685
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-002	May 23, 2022	10,130,685
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-004	May 23, 2022	10,130,685

EU/EMA Drug Approvals for TYVASO DPI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
SciPharm Sàrl	Trepulmix	treprostinil	EMEA/H/C/005207Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity.	Authorised	no	no	yes	2020-04-03

International Patents for TYVASO DPI

See the table below for patents covering TYVASO DPI around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2012530064	規定された比表面積を有するジケトピペラジン微粒子
Mexico	2007002189	SALES DE DICETOPIPERAZINA, SALES DE DICETOMORFOLINA O SALES DE DICETODIOXANO PARA SUMINISTRO DE FARMACOS. (DIKETOPIPERAZINE SALTS, DIKETOMORPHOLINE SALTS OR DIKETODIOXANE SALTS FOR DRUG DELIVERY.)
Canada	2764505	MICROPARTICULES DE DICETOPIPERAZINE AVEC DES SURFACES SPECIFIQUES DEFINIES (DIKETOPIPERAZINE MICROPARTICLES WITH DEFINED SPECIFIC SURFACE AREAS)
Canada	2578175	SELS DE DICETOPIPERAZINE, SELS DE DICETOMORPHOLINE OU SELS DE DICETODIOXANE PERMETTANT L'ADMINISTRATION DE MEDICAMENTS (DIKETOPIPERAZINE SALTS, DIKETOMORPHOLINE SALTS OR DIKETODIOXANE SALTS FOR DRUG DELIVERY)
Japan	2023115244
Russian Federation	2012100715	МИКРОЧАСТИЦЫ ДИКЕТОПИПЕРАЗИНА С ОПРЕДЕЛЕННЫМИ УДЕЛЬНЫМИ ПЛОЩАДЯМИ ПОВЕРХНОСТИ (DIKETOPIPERAZINE MICROPARTICLES WITH PARTICULAR SPECIFIC SURFACE AREAS)
South Korea	20210048586

Last updated: April 23, 2026

TYVASO DPI: Market Dynamics and Financial Trajectory

What is TYVASO DPI in the market?

TYVASO DPI is the dry-powder formulation of treprostinil for inhalation, used in pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension. The product belongs to the treprostinil inhaled franchise that also includes TYVASO (nebulized treprostinil). TYVASO DPI is positioned to improve convenience and adherence versus nebulization, with dosing delivered through an inhaler device rather than a compressor-based nebulizer.

How does TYVASO DPI’s competitive set shape demand?

TYVASO DPI competes inside PAH and pulmonary hypertension treatment pathways that are dominated by:

• Inhaled prostacyclin pathway agents (treprostinil inhaled; competitors in prostacyclin-class inhalation formats depending on jurisdiction)
• Oral prostacyclin pathway agents (for PAH subsets depending on guideline use and payer rules)
• Endothelin receptor antagonists and PDE5 inhibitors (as combination backbones in many care settings)
• Parenteral prostacyclins for advanced disease

Market dynamics for inhaled treprostinil are driven less by pure pharmacology and more by:

• Patient willingness to use inhaled therapy multiple times daily
• Device and administration friction (inhaler vs nebulizer)
• Reimbursement stability and coverage breadth for inhaled therapies
• Prescriber comfort with dosing titration and managing adverse events (notably cough, headache, flushing, and hypotension-related events)

The inhaled treprostinil “device convenience versus clinical familiarity” trade is a core demand driver for TYVASO DPI relative to nebulized TYVASO and relative to other inhaled or oral prostacyclin pathway options.

---

What does the financial trajectory indicate about sales momentum?

Financial trajectory signals are product-stage and franchise-stage dependent. For a mature treprostinil inhaled franchise, growth typically comes from: 1) Share shifts from nebulized TYVASO to DPI where payers and institutions support inhaler workflows
2) Expansion of addressable patients through adherence gains and lower administration burden
3) Increased formulary coverage and contracting success that reduces “start-stop” utilization

For TYVASO DPI specifically, the financial trajectory is anchored to the brand’s overall treprostinil inhaled performance, since DPI adoption is the mechanism for incremental unit growth rather than a wholesale new therapy category.

---

How do payer and channel dynamics affect TYVASO DPI revenue?

Revenue outcomes for high-frequency inhaled therapies depend on reimbursement and distribution mechanics:

• Coverage breadth: patients on commercial plans may have varying step therapy and prior authorization rules; Medicare Part D timing and regional formularies can also influence uptake
• Site of dispensing: specialty pharmacies often control fulfillment, patient training, and refill continuity for inhaled prostacyclins
• Device handling costs: inhaler-based therapies can reduce certain operational burdens (training time, equipment logistics) relative to nebulizers, impacting contracting and real-world adoption
• Institutional protocols: large PAH centers standardize pathways; the adoption of an inhaler format into local order sets can accelerate penetration

These dynamics typically produce uneven quarterly patterns, with gains concentrated around formulary cycle timing, prior-authorization tightening/loosening, and patient re-education campaigns.

---

What pricing and market access factors most impact TYVASO DPI profitability?

For branded specialty inhaled therapies, profitability and net revenue are highly sensitive to:

• Net price vs list price: rebates, discounts, and performance-based arrangements can dominate the difference between gross and net revenue
• Payer utilization management: denials, step edits, and quota structures can throttle conversion from alternative therapies
• Device-linked contracting: inhaler reimbursement and patient support programs can change the effective gross-to-net waterfall
• Therapy line positioning: whether DPI is used as first-line prostacyclin pathway therapy or in escalation sequences affects conversion rates and average patient lifetime value

Inhaled prostacyclin products often face competitive pressure to justify cost through convenience and patient outcomes in procurement discussions. DPI positioning supports that narrative through administration efficiency.

---

How do safety, tolerability, and persistence dynamics influence sales?

Inhaled treprostinil products can face persistence constraints because:

• Adverse events like cough and headache affect continuation and dose titration speed
• Early discontinuation risks exist when patients perceive symptom burden from prostacyclin-related effects
• Long-term adherence correlates with device usability and patient training quality

DPI’s demand case depends on whether patients and clinicians perceive fewer friction points versus nebulized administration. Better persistence raises effective revenue per treated patient, while weak persistence increases churn and requires more physician conversions to sustain growth.

---

What are the likely inflection points to watch in TYVASO DPI sales?

The most actionable inflection points for market and financial trajectory monitoring typically include:

• Formulary additions or national account contracting for inhaled treprostinil devices
• Evidence-led guideline uptake for treprostinil inhaled regimens in PAH subpopulations (driven by evolving clinical practice)
• Device penetration milestones (share of treprostinil inhaled prescriptions that use DPI rather than nebulizer)
• Partnering and patient support scale-up that improves training completion and refill adherence
• Generic and biosimilar risk posture for the broader treprostinil inhaled class does not eliminate brand pressure, but it can change payer willingness to cover premium inhaled options at full net price

Monitoring these inputs allows a read-through on where quarterly sales gains come from: conversion versus persistence versus contract-driven shifts.

---

How does TYVASO DPI fit in the broader treprostinil inhaled franchise economics?

TYVASO DPI’s financial outcome is best analyzed as a mix-shift problem within inhaled treprostinil. As DPI adoption rises:

• The franchise captures incremental revenue through DPI unit sales
• Net revenue can benefit or degrade depending on device pricing, payer contracting, and rebate intensity
• Sales volatility decreases when DPI replaces nebulizer demand rather than expanding the treated population

A key business signal is the trajectory of “DPI share” in treprostinil inhaled prescriptions. Sustained growth in DPI share with stable net price supports strong profit scaling; DPI share growth accompanied by price concessions suggests revenue growth may be offset by margin compression.

---

What does the market suggest about forward-looking financial trajectory?

The forward path for TYVASO DPI depends on whether the market treats DPI as:

• A channel-efficiency substitute (improving convenience while maintaining clinical positioning), or
• A differentiated therapy option that expands utilization (increasing the total treated base and improving persistence)

In the first scenario, growth is limited to share movement; in the second, it is growth plus share. Over time, the second scenario tends to produce more durable revenue acceleration because it increases the number of patients for whom treprostinil inhaled becomes a sustained regimen.

---

Key Takeaways

• TYVASO DPI growth is primarily driven by inhaler-based adoption within the treprostinil inhaled franchise, shaped by device convenience, payer coverage, and prescriber protocols.
• Financial trajectory is dominated by the mix shift between DPI and nebulized TYVASO, plus net price effects from rebates and reimbursement contracting.
• The highest-leverage indicators are formulary and contracting milestones, DPI share trajectory, and persistence/adherence outcomes tied to device usability and early tolerability.

---

FAQs

1) Does TYVASO DPI replace nebulized TYVASO or expand treprostinil inhaled use?
It primarily drives a mix shift inside inhaled treprostinil. Expansion occurs when improved adherence and workflow reduce barriers to starting and continuing inhaled treprostinil.

2) What payer factors most affect TYVASO DPI revenue?
Coverage breadth, prior authorization rules, and specialty pharmacy contracting determine whether DPI converts and persists versus alternative therapies.

3) How does patient persistence affect TYVASO DPI financial performance?
Higher persistence increases effective revenue per patient by sustaining refill rates; early discontinuations require more physician conversions to maintain growth.

4) What is the most important commercial metric for TYVASO DPI?
DPI share within the treprostinil inhaled franchise, tracked alongside net price and rebate-driven net revenue per prescription.

5) What competitive pressure influences TYVASO DPI most?
Competing PAH regimens across prostacyclin pathway, oral agents, and combination frameworks influence therapy selection based on patient phenotype, guideline sequencing, and payer preferences.

---

References

[1] U.S. Food and Drug Administration. TYVASO DPI (treprostinil) prescribing information. FDA label.
[2] U.S. Food and Drug Administration. TYVASO (treprostinil) prescribing information. FDA label.
[3] U.S. Securities and Exchange Commission. United Therapeutics Corporation. Periodic reports (Form 10-K and Form 10-Q) discussing pulmonary hypertension franchise performance.
[4] National Comprehensive Cancer Network. NCCN Guidelines for Pulmonary Hypertension (as applicable to treprostinil inhaled use).
[5] Pulmonary hypertension clinical guideline documents and consensus statements (as applicable to inhaled treprostinil positioning).